AstraZeneca

Pfizer chief Ian Read's pay falls 23%

Pfizer said that net compensation of chief executive officer Ian Read declined 23% in 2015 driven by a drop in stock awards. The chief's net compensation amounted to $18 million in 2015.

Read Full Article

AstraZeneca investors want boss pay to link with revenue target

AstraZeneca is facing serious issues with regard to its executive salary after a profit cautioning. Investors want the company to link Pascal Soriot's pay with revenue target.

Read Full Article

Valeant partners with AstraZeneca for psoriasis drug

Valeant Pharmaceuticals, Inc. of Canada has partnered with AstraZeneca for the selling rights of psoriasis drug brodalumab. Amgen Inc. ended its partnership with AstraZeneca due to its worries over the drug's side effects.

Read Full Article

AstraZeneca would consider buying immune-therapy company: Bloomberg

AstraZeneca Plc (AZN.L) (AZN.N) would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body's immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday.

Read Full Article

AstraZeneca CEO says new Pfizer bid unlikely

U.S. Pfizer is unlikely to come back with a fresh bid for AstraZeneca, the Anglo-Swedish pharmaceuticals group's top executive was quoted as saying by Swedish business daily Dagens Industri on Saturday.

Read Full Article

Novartis psoriasis drug tops J&J's Stelara in late-stage study

Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara.

Read Full Article

Pfizer dampens Astra bid hopes with German Merck cancer deal

Pfizer (PFE.N) dampened investors' expectations of a renewed bid for AstraZeneca (AZN.L) on Monday by signing a major cancer drug deal with Germany's Merck KGaA (MRCG.DE), reducing the U.S. firm's need for Astra's products.

Read Full Article

Tax changes weaken case for new Pfizer bid, says AstraZeneca CEO

Recent U.S. tax changes have weakened the case for companies like Pfizer (PFE.N) to shift their tax bases overseas by striking so-called tax inversion deals, according to AstraZeneca's (AZN.L) chief executive.

Read Full Article

AstraZeneca strengthens cancer business with new deals

AstraZeneca moved to strengthen its core oncology business on Tuesday with three deals designed to expand the British drugmaker's reach in treating tumors.

Read Full Article

Pfizer beats sales and profit forecasts, mum on future deals

Pfizer Inc (PFE.N) reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc (AZN.L).

Read Full Article

AstraZeneca looks to EU decision for next cancer drug boost

AstraZeneca's cancer drug pipeline, already on a roll following promising clinical trial results, could get a further boost next week from a European green light for an experimental medicine against ovarian cancer.

Read Full Article

Plant-based vaccines challenge big pharma for $3 billion flu market

Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

Read Full Article

AstraZeneca, Shire fall as U.S. tax move punctures deal hopes

Shares in drugmakers AstraZeneca (AZN.L) and Shire (SHP.L) both fell more than 5 percent on Tuesday after the U.S. Treasury took steps to curb "inversion" deals that allow companies to escape high U.S. taxes by reincorporating abroad.

Read Full Article

'Back to normal' for AstraZeneca CEO, despite Pfizer rumors

Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Instead, he has spent the last three days immersed in heart science in Barcelona.

Read Full Article

AstraZeneca inks deal with Medical Research Council scientists to work on new site in Cambridge

Britain-based AstraZeneca has formed a flagship deal with Medical Research Council or MRC to hopefully help the drugmaker revive research on new drugs, Reuters reported.

Read Full Article
1 2

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics